OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations
Dimitrios A. Vrachatis, Konstantinos A. Papathanasiou, Konstantinos Iliodromitis, et al.
Drugs (2021) Vol. 81, Iss. 12, pp. 1381-1395
Closed Access | Times Cited: 12
Dimitrios A. Vrachatis, Konstantinos A. Papathanasiou, Konstantinos Iliodromitis, et al.
Drugs (2021) Vol. 81, Iss. 12, pp. 1381-1395
Closed Access | Times Cited: 12
Showing 12 citing articles:
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis
Chao Li, Jie Yu, Carinna Hockham, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 10, pp. 1927-1938
Open Access | Times Cited: 22
Chao Li, Jie Yu, Carinna Hockham, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 10, pp. 1927-1938
Open Access | Times Cited: 22
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
Veronika A. Myasoedova, Michele Bozzi, Vincenza Valerio, et al.
Antioxidants (2023) Vol. 13, Iss. 1, pp. 16-16
Open Access | Times Cited: 12
Veronika A. Myasoedova, Michele Bozzi, Vincenza Valerio, et al.
Antioxidants (2023) Vol. 13, Iss. 1, pp. 16-16
Open Access | Times Cited: 12
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Zi‐Wei Yin, Huizhen Zheng, Zhihua Guo
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 16
Zi‐Wei Yin, Huizhen Zheng, Zhihua Guo
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 16
A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation
Nikolaos Karamichalakis, Vasileios Kolovos, Ioannis Paraskevaidis, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 8, pp. 236-236
Open Access | Times Cited: 10
Nikolaos Karamichalakis, Vasileios Kolovos, Ioannis Paraskevaidis, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 8, pp. 236-236
Open Access | Times Cited: 10
A comparison of medical therapy and ablation for atrial fibrillation in patients with heart failure
Peter Calvert, J Farinha, Dhiraj Gupta, et al.
Expert Review of Cardiovascular Therapy (2022) Vol. 20, Iss. 3, pp. 169-183
Closed Access | Times Cited: 8
Peter Calvert, J Farinha, Dhiraj Gupta, et al.
Expert Review of Cardiovascular Therapy (2022) Vol. 20, Iss. 3, pp. 169-183
Closed Access | Times Cited: 8
The complex interplay between diabetes mellitus and atrial fibrillation
Mehmet Yildiz, Carl J. Lavie, Daniel P. Morin, et al.
Expert Review of Cardiovascular Therapy (2022) Vol. 20, Iss. 9, pp. 707-717
Closed Access | Times Cited: 6
Mehmet Yildiz, Carl J. Lavie, Daniel P. Morin, et al.
Expert Review of Cardiovascular Therapy (2022) Vol. 20, Iss. 9, pp. 707-717
Closed Access | Times Cited: 6
Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review
Dimitrios A. Vrachatis, Konstantinos A. Papathanasiou, Sotiria G. Giotaki, et al.
Current Pharmaceutical Design (2023) Vol. 29, Iss. 7, pp. 509-518
Closed Access | Times Cited: 3
Dimitrios A. Vrachatis, Konstantinos A. Papathanasiou, Sotiria G. Giotaki, et al.
Current Pharmaceutical Design (2023) Vol. 29, Iss. 7, pp. 509-518
Closed Access | Times Cited: 3
Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling
Ioan‐Alexandru Minciună, Raluca Tomoaia, Dragos Mihăilă, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 9, pp. 9607-9623
Open Access
Ioan‐Alexandru Minciună, Raluca Tomoaia, Dragos Mihăilă, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 9, pp. 9607-9623
Open Access
Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, d’arythmies ventriculaires et de mort subite
André Scheen
Médecine des Maladies Métaboliques (2022)
Closed Access | Times Cited: 1
André Scheen
Médecine des Maladies Métaboliques (2022)
Closed Access | Times Cited: 1
